Mobility Protocol Adapted for Advanced Visually Impaired Subjects
Design of a Mobility Protocol to Assess the Impact of Visual Pathologies in Daily Life Activities for Subjects With Advanced Visual Deficits
Retinitis Pigmentosa is characterized by a progressive disappearance of photoreceptors,
responsible for a progressive and severe loss of vision.
People Retinitis Pigmentosa therefore encounter a large number of difficulties in daily life,
- Visual research
- Visuo-motor coordination in tasks requiring fine motor control
- Visuo-motor coordination in mobility tasks
This study aims to assess the difficulties in the daily life of subjects with Retinitis
Pigmentosa at a very advanced stage unsing, quaify of life questionnaires, simplified
locomotion tasks in real situation and a posture task.
They are proposing a new test adapted and carried out in real situations, in binocular and
monocular vision, making it possible to finely assess locomotion especially for "very low
This test will also ultimately make it possible to better evaluate the effectivements, that
is to say to observe and quantify objectively by a score the performance progression obtained
for locomotion tasks related to the visual recovery generated by the treatment.
This is monocentric study and the total duration of the study is 48 months. The duration of
participation for each research subject is 3 months and maximum 4 visits. This is research
involving the human type of non-invasive interventional research, with minimal risks and
This exploratory study will be conducted on a group of patients with Retinitis Pigmentosa at
a very advanced stage.
There will be an inclusion visit including a visual assessment and an ophthalmological
consultation. Two experimental visits with tests carried out in a real environment including
a locomotion and a posture tasks. An end-of-study visit within a maximum of 1 month following
the second experimental visit.
Measurement of postural parameters
Study Arms / Comparison Groups
Retinitis Pigmentosa patients
Description: 50 patients with very severe Retinitis Pigmentosa
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
March 2, 2020
June 4, 2024
Primary Completion Date
June 2, 2024
- Retinitis Pigmentosa, non-syndromic, the diagnosis of which has been confirmed by an
- ETDRS visual acuity less than 2/10 (>+0.7 logMAR; <20/100 Snellen)
- Doesn't participate in clinical research that may interfere with this study
- Sufficient knowledge of the French language to ensure a perfect understanding of the
tasks to be performed and the instructions received
- Consent to the study signed after information by the investigator
- Health insurance affiliation
- Pregnant women
- Inability to give personal consent
- Cataract surgery in the 3 months preceding inclusion
- Inability to comply with the instructions for carrying out the study tasks or to
complete the study visits
- MMSE score without visual item ≤ 20/25
- Drug treatment which can lead to motor, visual or cognitive disorders (PSA,
neuroleptics,etc.) or which may interfere with the study's evaluations